Correlation Between Supernus Pharmaceuticals and Xeris Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Supernus Pharmaceuticals and Xeris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Supernus Pharmaceuticals and Xeris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Supernus Pharmaceuticals and Xeris Pharmaceuticals, you can compare the effects of market volatilities on Supernus Pharmaceuticals and Xeris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Supernus Pharmaceuticals with a short position of Xeris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Supernus Pharmaceuticals and Xeris Pharmaceuticals.

Diversification Opportunities for Supernus Pharmaceuticals and Xeris Pharmaceuticals

-0.67

Correlation Coefficient

Supernus Pharmaceuticals  Xeris Pharmaceuticals

Excellent diversification

The 3 months correlation between Supernus and Xeris is -0.67. Overlapping area represents the amount of risk that can be diversified away by holding Supernus Pharmaceuticals and Xeris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xeris Pharmaceuticals and Supernus Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Supernus Pharmaceuticals are associated (or correlated) with Xeris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xeris Pharmaceuticals has no effect on the direction of Supernus Pharmaceuticals i.e., Supernus Pharmaceuticals and Xeris Pharmaceuticals go up and down completely randomly.

Pair Corralation between Supernus Pharmaceuticals and Xeris Pharmaceuticals

Given the investment horizon of 90 days Supernus Pharmaceuticals is expected to under-perform the Xeris Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Supernus Pharmaceuticals is 1.14 times less risky than Xeris Pharmaceuticals. The stock trades about -0.05 of its potential returns per unit of risk. The Xeris Pharmaceuticals is currently generating about 0.26 of returns per unit of risk over similar time horizon. If you would invest  349.00  in Xeris Pharmaceuticals on December 20, 2024 and sell it today you would earn a total of  202.00  from holding Xeris Pharmaceuticals or generate 57.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Supernus Pharmaceuticals  vs.  Xeris Pharmaceuticals

Supernus Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Supernus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest inconsistent performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Xeris Pharmaceuticals

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Supernus Pharmaceuticals and Xeris Pharmaceuticals

The main advantage of trading using opposite Supernus Pharmaceuticals and Xeris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Supernus Pharmaceuticals position performs unexpectedly, Xeris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xeris Pharmaceuticals will offset losses from the drop in Xeris Pharmaceuticals' long position.

The idea behind Supernus Pharmaceuticals and Xeris Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..